These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 8113988)
1. Effects of nicorandil on cytosolic calcium concentrations and on tension development in the rabbit femoral artery. Abe S; Nishimura J; Nakamura M; Kanaide H J Pharmacol Exp Ther; 1994 Feb; 268(2):762-71. PubMed ID: 8113988 [TBL] [Abstract][Full Text] [Related]
2. The effects of a novel vasodilator, LP-805, on cytosolic Ca2+ concentrations and on tension in rabbit isolated femoral arteries. Ushio-Fukai M; Hirano K; Kanaide H Br J Pharmacol; 1994 Dec; 113(4):1173-82. PubMed ID: 7889270 [TBL] [Abstract][Full Text] [Related]
3. Nicorandil-induced vasorelaxation: functional evidence for K+ channel-dependent and cyclic GMP-dependent components in a single vascular preparation. Meisheri KD; Cipkus-Dubray LA; Hosner JM; Khan SA J Cardiovasc Pharmacol; 1991 Jun; 17(6):903-12. PubMed ID: 1714013 [TBL] [Abstract][Full Text] [Related]
4. Effects of 2-nicotinamidoethyl nitrate (nicorandil; SG-75) and its derivative on smooth muscle cells of the canine mesenteric artery. Inoue T; Kanmura Y; Fujisawa K; Itoh T; Kuriyama H J Pharmacol Exp Ther; 1984 Jun; 229(3):793-802. PubMed ID: 6233418 [TBL] [Abstract][Full Text] [Related]
5. The inhibitory mechanisms of nicorandil in isolated rat urinary bladder and femoral artery. Zhou Q; Satake N; Shibata S Eur J Pharmacol; 1995 Jan; 273(1-2):153-9. PubMed ID: 7737309 [TBL] [Abstract][Full Text] [Related]
6. Effects of nicorandil on cytosolic calcium concentrations in quin2-loaded rat aortic vascular smooth muscle cells in primary culture. Kai H; Kanaide H; Nakamura M J Pharmacol Exp Ther; 1989 Dec; 251(3):1174-80. PubMed ID: 2557415 [TBL] [Abstract][Full Text] [Related]
7. The dualistic mode of action of the vasodilator drug, nicorandil, differentiated by glibenclamide in 86Rb flux studies in rabbit isolated vascular smooth muscle. Kreye VA; Lenz T; Theiss U Naunyn Schmiedebergs Arch Pharmacol; 1991 Jan; 343(1):70-5. PubMed ID: 1827659 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of nicorandil by 86Rb efflux and isometric vasorelaxation studies in vascular smooth muscle. Kreye VA; Lenz T; Pfründer D; Theiss U J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S8-12. PubMed ID: 1282181 [TBL] [Abstract][Full Text] [Related]
9. Nicorandil: differential contribution of K+ channel opening and guanylate cyclase stimulation to its vasorelaxant effects on various endothelin-1-contracted arterial preparations. Comparison to aprikalim (RP 52891) and nitroglycerin. Borg C; Mondot S; Mestre M; Cavero I J Pharmacol Exp Ther; 1991 Nov; 259(2):526-34. PubMed ID: 1682478 [TBL] [Abstract][Full Text] [Related]
10. K+ channel opening mediates the vasorelaxant effects of nicorandil in the intact vascular system. Cavero I; Pratz J; Mondot S Z Kardiol; 1991; 80 Suppl 7():35-41. PubMed ID: 1838848 [TBL] [Abstract][Full Text] [Related]
11. Analysis of relaxation and repolarization mechanisms of nicorandil in rat mesenteric artery. Fujiwara T; Angus JA Br J Pharmacol; 1996 Dec; 119(8):1549-56. PubMed ID: 8982500 [TBL] [Abstract][Full Text] [Related]
12. The contribution of guanylate cyclase stimulation and K+ channel opening to nicorandil-induced vasorelaxation depends on the conduit vessel and on the nature of the spasmogen. Magnon M; Durand I; Cavero I J Pharmacol Exp Ther; 1994 Mar; 268(3):1411-8. PubMed ID: 7908056 [TBL] [Abstract][Full Text] [Related]
13. K+ channel-opening action contributes to the preventive effects of nicorandil on U46619-induced vasoconstriction of canine large coronary arteries in vivo. Kamijo T; Iwai T; Haruta K; Takeda K Arch Int Pharmacodyn Ther; 1996; 331(3):273-84. PubMed ID: 9124999 [TBL] [Abstract][Full Text] [Related]
14. Possible involvement of ATP-sensitive K+ channels in the relaxant response of dog middle cerebral artery to cromakalim. Masuzawa K; Asano M; Matsuda T; Imaizumi Y; Watanabe M J Pharmacol Exp Ther; 1990 Nov; 255(2):818-25. PubMed ID: 2123008 [TBL] [Abstract][Full Text] [Related]
15. Differential antagonism by glibenclamide of the relaxant effects of cromakalim, pinacidil and nicorandil on canine large coronary arteries. Satoh K; Yamada H; Taira N Naunyn Schmiedebergs Arch Pharmacol; 1991 Jan; 343(1):76-82. PubMed ID: 1827660 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological interaction experiments differentiate between glibenclamide-sensitive K+ channels and cyclic GMP as components of vasodilation by nicorandil. Holzmann S; Kukovetz WR; Braida C; Pöch G Eur J Pharmacol; 1992 Apr; 215(1):1-7. PubMed ID: 1325362 [TBL] [Abstract][Full Text] [Related]
18. Specific but differential antagonism by glibenclamide of the vasodepressor effects of cromakalim and nicorandil in spinally-anaesthetized dogs. Yamada H; Yoneyama F; Satoh K; Taira N Br J Pharmacol; 1990 Jul; 100(3):413-6. PubMed ID: 2143956 [TBL] [Abstract][Full Text] [Related]
19. Cytoplasmic calcium and the relaxation of canine coronary arterial smooth muscle produced by cromakalim, pinacidil and nicorandil. Yanagisawa T; Teshigawara T; Taira N Br J Pharmacol; 1990 Sep; 101(1):157-65. PubMed ID: 2149290 [TBL] [Abstract][Full Text] [Related]
20. Relaxant effect of nicorandil on the tonic contraction of the canine large coronary artery induced by phorbol 12,13-dibutylate. Kuromaru O; Sakai K Arch Int Pharmacodyn Ther; 1995; 330(1):25-38. PubMed ID: 8849308 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]